In other recent news, Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, delivering results that surpassed expectations. The company posted an earnings per share (EPS) of -$0.21, ...
Recursion has merged Exscientia’s AI-driven chemistry with its own phenomics and a new ClinTech real-world-data capability to streamline discovery and trials, consolidated R&D to five internal ...
Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...
SALT LAKE CITY - Recursion (NASDAQ:RXRX) announced Monday that Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026, replacing David Mauro, M.D., Ph.D., who is transitioning ...
GPU behemoth Nvidia’s most important metric probably isn’t its data center revenue, hyperscaler capex trends, or the yield on its latest chips. It it is barely talked about by semiconductor analysts ...
Sat, March 21, 2026 at 10:45 AM UTC Drug discovery is broken. The industry average is 2,500 compounds synthesized over 42 months to find one development candidate. Recursion Pharmaceuticals (NASDAQ: ...
Short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) decreased during the last reporting period, falling from 174.14M to 173.93M. This put 35.4% of the company's publicly available shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results